USFDA issues response letter for new drug application for insulin glargine: Biocon
Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2019 Category: Pharmaceuticals Source Type: news
insulin glargine (Lantus)
Title: insulin glargine (Lantus)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 7/1/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 1, 2019 Category: Endocrinology Source Type: news
Insulin glargine cost  effective versus NPH insulin in Hong Kong
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
[1-12-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
ADA: Combo Injectable Controls Blood Glucose Longer in T2DM
FRIDAY, June 14, 2019 -- Compared with insulin glargine, initial injectable therapy with a combination of insulin degludec and liraglutide aids achievement of blood glucose goals for a longer period of time in patients with uncontrolled type 2... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2019 Category: Pharmaceuticals Source Type: news
Combination medication helps patients with type 2 diabetes maintain blood sugar goals
(Brigham and Women's Hospital) Through a randomized, multicenter clinical trial, investigators studied blood glucose results for patients assigned to either take insulin (insulin glargine, IGlar U100) or insulin degludec plus liraglutide (IDegLira), a combination of both insulin and an additional medication to help with blood sugar control. The global study team found that participants who received IDegLira were better able to achieve blood glucose goals and remain at that goal longer compared to those assigned to receive IGlar. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2019 Category: International Medicine & Public Health Source Type: news
FDA Expands Indication for Soliqua 100/33 (insulin glargine and lixisenatide injection) to Include Type 2 Diabetes Patients Uncontrolled on Oral Antidiabetic Medicines
BRIDGEWATER, N.J., Feb. 27, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL. Previously approved for use as an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 27, 2019 Category: Drugs & Pharmacology Source Type: news
Study: Even Older Drugs Getting Steep Price Hikes
The cost of a two-pack EpiPen injector has increased from around $100 in 2007 to between $300 and $600 today. The list price for Lantus brand insulin increased by 49 percent in 2014, even though the product has been on the market for more than a decade. (Source: WebMD Health)
Source: WebMD Health - January 8, 2019 Category: Consumer Health News Source Type: news
Metformin vs. Lantus
Title: Metformin vs. LantusCategory: MedicationsCreated: 12/20/2018 12:00:00 AMLast Editorial Review: 12/20/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 20, 2018 Category: Drugs & Pharmacology Source Type: news
Mylan says Sanofi loses Lantus insulin patent claims
U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials
HERTFORDSHIRE, England and PITTSBURGH, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N... Biopharmaceuticals, Generics, Endocrinology, Litigation Mylan, Sanofi, Lantus, insulin glargine, Lantus SoloSTAR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news
Mylan wins lawsuit over insulin formulation patents
Mylan announced Thursday that the U.S. Patent and Trademark Appeal Board had ruled in its favor, allowing the Canonsburg-based pharmaceutical company to continue making a generic insulin glargine vial.
Mylan has spent years investing in a generic insulin glargine, which is used by diabetes patients to control their blood sugar. The insulin glargine, marketed as Lantus, was created by French pharmaceutical company Sanofi and is sold in vials or as a disposable injection pen.
Sanofi initiated pa tent… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 13, 2018 Category: Pharmaceuticals Authors: Luke Torrance Source Type: news
Sanofi loses Lantus patent claims against Mylan
U.S. generics drugmaker Mylan N.V. said on Thursday the U.S. Patent and Trademark Office rejected French pharma company Sanofi's patent infringement claims related to two formulations of its blockbuster insulin drug Lantus. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan says patent office cancels Sanofi's Lantus patents
Mylan N.V. said on Thursday the U.S. Patent and Trademark Office invalidated French drug company Sanofi's formulation patents on its blockbuster insulin drug Lantus, ruling in favor of the U.S. drugmaker. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
IDegLira vs Insulin Glargine U100 Plus Insulin Aspart IDegLira vs Insulin Glargine U100 Plus Insulin Aspart
Is IDegLira a more cost-effective treatment choice for type 2 diabetes than insulin glargine U100 plus insulin aspart?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
